Proktoverin rectal suppositories №5х2

Name: Proctoverin Description: Torpedo-shaped suppositories from white to light yellow. Color heterogeneity from white to light yellow and the presence of a funnel-shaped depression are allowed. Release form Suppositories. Special instructions The drug is contraindicated in children and adolescents under 18 years of age. When driving vehicles and operating mechanisms, care must be taken due to the possibility of developing side effects of papaverine hydrochloride, for example, drowsiness and dizziness. Indications for use As part of complex therapy in patients with grade I-II hemorrhoids in the acute phase. Dosage and administration Use the drug after hygiene procedures. Wash the skin around the anus with warm water or clean it with a moistened soft cloth, dry gently with toilet paper or a soft cloth. Before the introduction of the suppository, it is necessary to remove the protective plastic shell from it. The drug is injected into the rectum 1 suppository 2 times a day until the disappearance of acute clinical symptoms. After improving the clinical picture, they switch to the introduction of 1 suppository 1 time per day. The duration of the course of treatment is determined by the attending physician. Do not use for a long period of time. To obtain the maximum therapeutic effect, it is recommended to use the drug after defecation. Use during pregnancy and lactation The drug is contraindicated during pregnancy and lactation. Clinical studies of the drug in pregnant and lactating women have not been conducted. Interaction with other drugs No interaction studies have been conducted with other medicinal products. Cholinesterase inhibitors inhibit the metabolism of benzocaine. Benzocaine reduces the antimicrobial activity of sulfonamides. Cetylpyridinium is incompatible with soaps and other anionic surfactants. Papaverine hydrochloride, when used simultaneously, potentiates the effect of alcohol, weakens the hypotensive effect of methyldopa, can reduce the anti-Parkinsonian effect of levodopa, enhance the effect of calcium channel blockers and drugs that depress the central nervous system, and shows synergism in combination with morphine. Nicotine is able to reduce or completely eliminate the vasodilating effect of papaverine hydrochloride. When combined with antiarrhythmic and antihypertensive drugs, it is possible to increase the hypotensive effect. Metamizole (analgin), diphenhydramine (diphenhydramine), diclofenac potentiates the antispasmodic effect of papaverine hydrochloride. Do not co-administer with O-adrenergics (risk of arrhythmias). The effects of papaverine are potentiated by anesthetic, analgesic, sedative and tranquilizing substances. When combined with tricyclic antidepressants, procainamide, reserpine, quinidine, it is possible to increase the hypotensive effect of papaverine, with cardiac glycosides, there is a pronounced increase in myocardial contractile function due to a decrease in total peripheral vascular resistance. There is evidence of the development of hepatitis when combined with furadonin. Contraindications Hypersensitivity to the components of the drug; Allergic reactions to other local anesthetics in history; Children and adolescents up to 18 years of age; Age over 75 years (risk of developing hyperthermia); Pregnancy, lactation; Atrioventricular blockade, heart failure, myocardial infarction (acute and recently transferred), bradycardia, thromboembolism (including previously transferred); intracranial hypertension; Glaucoma; Severe liver dysfunction; Severe renal dysfunction; Severe disorders of the respiratory system, respiratory depression; Hyperplasia of the prostate; Oncological diseases; Inflammatory bowel disease, anorectal fistula, paraproctitis, portal hypertension, any other pathological condition in the anus, colon or rectum; Composition Per suppository: Active substances: benzocaine - 150 mg, papaverine hydrochloride - 20 mg, dexpanthenol - 50 mg, cetylpyridinium chloride - 2 mg; Excipients: anhydrous colloidal silicon dioxide, macrogol cetostearyl ether, solid fat. Precautions If bloody discharge from the anus, deterioration or in the absence of effect within 7 days, it is necessary to stop using the drug and seek medical advice. Conducting a proctological study and reviewing treatment tactics are necessary if the symptoms of hemorrhoids do not disappear after short-term therapy. When using drugs containing benzocaine, there have been reports of the development of methemoglobinemia (cyanosis of the skin, lips, nail plates, headache, dizziness, tachycardia, general weakness, respiratory failure), which can be fatal and requires emergency medical care. The risk of developing methemoglobinemia is higher in young children, the elderly, patients with hereditary disorders (deficiency of the enzymes glucose-6-phosphodiesterase, pyruvate kinase, NADH-methemoglobin reductase), heart disease, respiratory diseases (bronchial asthma, bronchitis, pulmonary emphysema), in case of smoking. Use with caution in elderly and debilitated patients, in patients with traumatic brain injury, adrenal insufficiency, hypothyroidism, prostatic hyperplasia, supraventricular tachycardia. With prolonged use of the drug, monitoring of blood counts is necessary. During the period of treatment, alcohol should be excluded. Overdose In case of a significant excess of the recommended doses, there may be a tendency to hypercoagulability, impaired vision (diplopia), weakness, drowsiness, dizziness, tachycardia, hypotension, heart rhythm disturbance, development of atrioventricular blockade, respiratory paralysis, intestinal atony, difficulty urinating. In the case of systemic absorption of benzocaine in case of overdose, disorders may develop: drowsiness, anxiety, agitation, in severe cases, convulsions. Treatment is symptomatic. In case of accidental ingestion of the drug, gastric lavage and enterosorbents are indicated. With an overdose of drugs containing benzocaine, the risk of developing methemoglobinemia (cyanosis of the skin, lips, nail plates, headache, dizziness, tachycardia, general weakness, respiratory failure) increases, which can be fatal and requires emergency medical care. If these symptoms appear, you should immediately contact the emergency department of the hospital. Side effects Undesirable reactions are presented below and classified by organ systems and frequency of development. The frequency of development is defined as follows: very often (≥ 1/10); often (from ≥ 1/100 to < 1/10); infrequently (from ≥ 1/1000 to < 1/100); rarely (from ≥ 1/10000 to < 1/1000); very rarely (< 1/10000); the frequency is unknown (cannot be established based on the available data). Immune system disorders: Infrequently: allergic reactions - local itching, swelling, urticaria, rash. Blood and lymphatic system disorders: Frequency unknown: methemoglobinemia (cyanosis of the skin, lips, nail plates, headache, dizziness, tachycardia, general weakness, respiratory disorders), eosinophilia. Gastrointestinal disorders: Rare: nausea, vomiting, constipation, diarrhea, elevated liver transaminases, dry mouth. Cardiovascular disorders: Rare: tachycardia, hypotension, cardiac arrhythmia, AV block. Nervous system disorders: Rare: dizziness, headache, drowsiness, weakness, lethargy, impaired attention. On the part of the organ of vision: Frequency unknown: visual impairment (diplopia). General disorders and disorders at the injection site: Infrequently: itching, burning in the anus. Rare: redness of the face. Frequency unknown: contact dermatitis, numbness in the anus. Other: Frequency unknown: increased sweating. In the event of adverse reactions, including those not listed in this leaflet, you should stop using the drug and consult a doctor. Storage conditionsStore at a temperature not exceeding 25°C. Keep out of the reach of children! Buy Proctoverin rectal suppositories No. 5x2 The price of Proctoverin rectal suppositories No. 5x2